Status:
COMPLETED
Catheter Ablation of Atrial Fibrillation in Patients With Pulmonary Hypertension Hypertension: a Randomised Study
Lead Sponsor:
General University Hospital, Prague
Conditions:
Atrial Fibrillation
Pulmonary Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Atrial fibrillation (AF) and atrial tachycardia (AT), including type I atrial flutter, are frequently observed in patients with pulmonary hypertension (PH). Catheter ablation of AF / AT has been estab...
Eligibility Criteria
Inclusion
- Pre-capillary PH (PAMP ≥25 mmHg; PAWP ≤15 mmHg) or combined post- a pre-capillary PH (PAMP ≥25 mmHg; PAWP \>15 mmHg; DPG ≥7 mmHg and/or PVR \>3 W.u.) of any etiology.
Exclusion
- Complex congenital heart defects (corrected or uncorrected)
- Isolated post-capillary PH (PAMP ≥25 mmHg; PAWP \>15 mmHg; DPG \<7 mmHg and/or PVR ≤ 3W.u.)
- Previous catheter ablation for AF / AT / AFL
- Previous or scheduled cardiac surgery-
- NYHA Class IV, cardiogenic shock
- Life expectancy \<1 year
- Non-compliance
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT04053361
Start Date
May 1 2018
End Date
December 31 2022
Last Update
February 26 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
FN Olomouc
Olomouc, Czechia, 77900
2
IKEM
Prague, Czechia, 10000
3
General University Hospital in Prague
Prague, Czechia, 12808